Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22616527 | 0.98 | PLAU (0.46) | PLAUPDGFRBPDGFRARAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL16240824 | 0.98 | PLAU (0.46) | PLAUPDGFRBPDGFRARAB9ANPC1 | |
| SCHEMBL30554705 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL17778295 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL21730396 | 0.82 | KDM1A (0.40) | PLAURAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL506497 | 0.82 | ALDH1A1 (0.55) | PLAUPDGFRBPDGFRARAB9ANPC1 | |
| SCHEMBL8371346 | 0.82 | PLAU (0.44) | PLAUPDGFRBPDGFRARAB9ANPC1 | |
| SCHEMBL27553086 | 0.81 | PDE10A (0.42) | PLAUPDGFRBPDGFRARAB9ANPC1 | |
| SCHEMBL9866203 | 0.80 | HRH1 (0.45) | PLAURAB9ANPC1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL11095592 | 0.80 | ALDH1A1 (0.53) | PLAUPDGFRBPDGFRARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4615439-A2 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | Humanwell Pharmaceutical US, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4326717-B1 | MODIFIED FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2025032440-A1 | KLF2 INDUCING COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4476229-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | Riparian Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240239780-A1 | MODIFIED FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240174693-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| WO-2024102754-A2 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | HUMANWELL PHARMACUETICAL US, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | PLAU 3205/4885PDGFRB 1347/4885PDGFRA 1603/4885 |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | SREBF2, LIPG, KLF5 | PLAU 2064/4885PDGFRB 392/4885PDGFRA 939/4885 |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | KLF5, KLF10, SREBF2 | PLAU 2612/4885PDGFRB 466/4885PDGFRA 1071/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | PLAU 3205/4885PDGFRB 1347/4885PDGFRA 1603/4885 |
| US-20240174693-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS | SSTR4, SSTR3, SSTR1 | PLAU 2966/4885PDGFRB 274/4885PDGFRA 288/4885 |
| US-20240239780-A1 | MODIFIED FERROPORTIN INHIBITORS | SLC40A1, HAMP, TFRC | PLAU 2505/4885PDGFRB 2794/4885PDGFRA 3252/4885 |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | PLAU 2745/4885PDGFRB 2108/4885PDGFRA 1355/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | PLAU 2115/4885PDGFRB 3819/4885PDGFRA 3893/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | PLAU 2844/4885PDGFRB 192/4885PDGFRA 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.